Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation

Abstract. Kirsten rat sarcoma (KRAS) mutation (KRASm) is associated with poor prognosis in non-small cell lung cancer (NSCLC) patients. We have aimed to survey NSCLC patients harboring KRASm in Taiwan, where never-smoking lung adenocarcinoma predominates, and analyze the immune checkpoint inhibitor...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Jia-Jun Wu, MD, Po-Hsin Lee, MD, Zhe-Rong Zheng, MD, Yen-Hsiang Huang, MD, Jeng-Sen Tseng, MD, PhD, Kuo-Hsuan Hsu, MD, Tsung-Ying Yang, MD, PhD, Sung-Liang Yu, PhD, Kun-Chieh Chen, MD, PhD, Gee-Chen Chang, MD, PhD
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Wolters Kluwer 2022-06-01
Seri Bilgileri:	Medicine
Online Erişim:	http://journals.lww.com/10.1097/MD.0000000000029381
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation

Benzer Materyaller